Qlife signs collaboration agreement with Hipro Biotechnology
Qlife has recently announced the signing of a Letter of Intent (LOI) with a leading industry partner, Hipro Biotechnology, as a component of its B2B strategy to enter key markets with the Egoo Health system. Qlife is now pleased to announce the signing of a collaboration agreement.The agreement in brief The agreement consists of four major parts: 1. Integration of reagents 2. Regulatory approval from the China Food and Drug Administration for Egoo Health 3. Distribution and sales of Egoo Health to Chinese hospitals 4. Production of Egoo Health Integration of Reagents The